Peritoneal dialysis medicinal composition with effect of improving side effects

A pharmaceutical composition and peritoneal dialysis technology, applied in the field of renal replacement therapy, can solve the problems of increased permeability, large side effects, loss of ultrafiltration function, etc.

Inactive Publication Date: 2010-09-22
傅毓秀 +1
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, long-term treatment of peritoneal dialysis fluid can lead to serious side effects, resulting in changes in the structure and function of the peritoneum, including thickening of the connective tissue under the peritoneum, increased permeability of the peritoneum to substances, and loss of ultrafiltration function. It is peritoneal fibrosis (Krediet RT. The peritoneal membrane in chronic peritoneal dialysis. KidneyInt 1996; 55: 341-356.)
Although there have been many studies in basic medicine, it has been found that drugs such as losartan can inhibit the fibrosis of the peritoneum, but these drugs have considerable side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peritoneal dialysis medicinal composition with effect of improving side effects
  • Peritoneal dialysis medicinal composition with effect of improving side effects
  • Peritoneal dialysis medicinal composition with effect of improving side effects

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1: In vitro culture of human umbilical cord mesenchymal stem cells

[0040] Human umbilical cords were collected aseptically and stored in HBSS (Biochrom L201-10) at 4°C for no more than 24 hours.

[0041] The umbilical cord was first soaked in 75% ethanol for 30 seconds to disinfect. Put the sterilized umbilical cord in a calcium-free and magnesium-free buffer solution (CMF, Gibco 14185-052) in a sterile operating table, cut the umbilical cord longitudinally with sterilized instruments, and cut the blood vessels and mesenchymal tissues ( Watton's gel) removed. The mesenchymal tissue was cut into 0.5 cm3 pieces and centrifuged at 250×g for 5 minutes. The supernatant was removed, and the precipitate was washed twice with an appropriate amount of serum-free DMEM (Gibco 12100-046), and then centrifuged at 250×g for 5 minutes. The mesenchymal tissue was treated with collagenase at 37°C for 14 to 18 hours. After washing, it was treated with 2.5% trypsin at 37°C...

Embodiment 2

[0042] Embodiment 2: In vitro culture of human peritoneal mesothelial cells

[0043] In this experiment, the greater omentum of patients after surgery was treated with 0.125% trypsin and 0.01% EDTA at 37°C for 25 minutes, and then washed with an appropriate amount of 10% FBS DMEM culture medium. skin cells.

Embodiment 3

[0044] Example 3: High-glucose dialysate will not cause damage to human umbilical cord mesenchymal stem cells cultured in vitro

[0045] Human umbilical cord mesenchymal stem cells were treated with DMEM medium: PD=1:2, 1:3, and 1:4 for 24 hours respectively, and observed by optical microscope, the cell morphology was similar to that of the control group treated with DMEM ( figure 1 A to 1H). Analysis by flow cytometry also found that umbilical cord mesenchymal stem cells will not be detected to be damaged ( figure 1 1 to 1N).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicinal composition for individual peritoneal dialysis, comprising umbilical mesenchymal stem cells. Specifically, the medicinal composition can be used for reducing side effects generated by the individual peritoneal dialysis.

Description

technical field [0001] The present invention relates to the technical field of renal replacement therapy. Specifically, the present invention provides a pharmaceutical composition for performing peritoneal dialysis in an individual, which includes umbilical cord mesenchymal stem cells. More specifically, the pharmaceutical composition of the present invention can be used to reduce the side effects of peritoneal dialysis in an individual. Background technique [0002] When the kidney tissue is irreversibly damaged due to disease, the kidney function gradually declines and enters the state of chronic renal insufficiency. Once the renal function drops to less than 10% of normal, it is end-stage renal failure. At this time, patients must cooperate with renal replacement therapy, that is, hemodialysis, peritoneal dialysis or kidney transplantation, to replace the function of the kidneys to remove waste and water, so as to maintain normal physiological functions. As of 2004, ab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/48A61P7/08A61K35/28
Inventor 傅毓秀
Owner 傅毓秀
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap